Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12286065 | 0.75 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPTSMN1; SMN2TSHR | |
| SCHEMBL12286063 | 0.72 | HDAC4 (0.41) | ALDH1A1KDM4EMAPTSMN1; SMN2TSHR | |
| SCHEMBL18501037 | 0.72 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTSMN1; SMN2TSHR | |
| SCHEMBL12286329 | 0.71 | MAPT (0.43) | ALDH1A1MAPTSMN1; SMN2TSHRPOLB | |
| SCHEMBL1417041 | 0.70 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTSMN1; SMN2TSHR | |
| SCHEMBL31376339 | 0.65 | KDM4E (0.46) | ALDH1A1KDM4EMAPTSMN1; SMN2TSHR | |
| SCHEMBL18832382 | 0.62 | RAB9A (0.59) | ALDH1A1KDM4EMAPTSMN1; SMN2TSHR | |
| SCHEMBL31376344 | 0.62 | HSP90AA1 (0.43) | KDM4EMAPTTSHRHSD17B10POLB | |
| SCHEMBL5474695 | 0.61 | KDM4E (0.39) | ALDH1A1KDM4EMAPTTSHRHSD17B10 | |
| SCHEMBL31303968 | 0.61 | KDM4E (0.46) | ALDH1A1KDM4EMAPTSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9566340-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566340-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2016-04-14 | — | — | US | disclosed |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2016-04-14 | — | — | US | disclosed |
| US-9198972-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198972-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2011100131-A9 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011100131-A2 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | DNMT1, FANCI, PCNA | ALDH1A1 1169/4885KDM4E 2182/4885MAPT 3501/4885 |
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | FANCI, PCNA, DNMT1 | ALDH1A1 971/4885KDM4E 1948/4885MAPT 3723/4885 |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | ALDH1A1 971/4885KDM4E 1948/4885MAPT 3723/4885 |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | ALDH1A1 971/4885KDM4E 1948/4885MAPT 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.